An observational study in Nasopharyngeal Carcinoma (NPC) and Screening, sponsored by Ming-Yuan Chen. Recruiting at 1 site in China. Open to participants aged 30 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Ming-Yuan Chen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen — 10 open to participants now, 10 under way, 3 of them phase 3. Nasopharyngeal Carcinoma · Ming-Yuan Chen.
Among the 10 studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen, this one is one of 2 that started in 2024, is the only observational one, and was the 4th registered.
683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.
Browse Nasopharyngeal Carcinoma studies →10 of the 10 studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen are open now, in 1 country. Recruiting first, the newest first:
Ming-Yuan Chen · Sites in China
Ages 18–75
Ming-Yuan Chen · Sites in China
Ages 18–70
Ming-Yuan Chen · Sites in China
Ages 18–65
Ming-Yuan Chen · Sites in China
Ages 18–70
Ming-Yuan Chen · Sites in China
Ages 18–70
By country, each count listing its studies:
Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.
This study: 30 Years to 69 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000,000 is above the median of 300 across 118 observational studies indexed under Nasopharyngeal Carcinoma.
Median enrollment 208 across the 9 interventional studies, 1,000,000 across the 1 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Ming-Yuan Chen is the lead sponsor of 12 studies on the registry; 12 are open to participants now.
1 of the studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07070479Ming-Yuan ChenCombination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish a comprehensive and integrated nasopharyngeal carcinoma screening cohort, which includes an epidemiological information database containing basic information, gender, age, ethnic and family history, dietary and lifestyle habits, and geographical environmental factors; a biobank of blood, tissue fluid, swabs, etc., for Epstein-Barr virus, tumors, and genetics; a clinical examination database including nasopharyngoscopy, imaging, pathology, and other examinations; and databases of Epstein-Barr virus and human genetic sequencing, etc.
This study aims to initiate a multicenter prospective nasopharyngeal carcinoma (NPC) screening cohort study around China, starting from regions with high incidence of NPC, to conduct a million-person-scale screening cohort study. Participants who meet the selection criteria will be included in the cohort. All participants will undergo an epidemiological information survey (including basic conditions, dietary and lifestyle habits, social, geographical, environmental, and other information) through questionnaires, and various samples such as blood, tissue fluid, and throat swabs will be collected. Quantitative testing or genetic sequencing will be conducted on Epstein-Barr virus (EBV) (including EBV-related proteins, antibodies, EBV DNA quantification and sequence length, methylation levels, and next-generation sequencing), nasopharyngeal epithelial or tumor cells, etc., to establish, validate, optimize, and promote the optimal combination screening strategy for NPC; participants defined as high-risk of NPC by screening will undergo clinical nasopharyngoscopy and combined imaging and pathological examinations to confirm NPC patients and provide them with precise clinical treatment; regular follow-ups of the entire cohort will be conducted to study the risk factors and molecular mechanisms of NPC. The purpose of this study is to establish a comprehensive and integrated data platform, primarily based on the population from the South China, including an NPC epidemiological information database based on the gender, age, ethnicity, dietary and lifestyle habits, and geographical environmental factors, a biobank based on various samples and screening test results, and a clinical examination database based on nasopharyngoscopy, head and neck MRI, and a database for EB virus and human genetic sequencing information, etc., forming a multi-source heterogeneous, open, and shared data platform. Based on this data platform, basic scientific and clinical research on NPC will be conducted, including: developing, validating, and optimizing new NPC screening markers and their composite screening programs, clarifying the target population for the promotion of NPC composite screening programs; research study of the etiology and risk factors of NPC from genetic, ethnic, geographical, environmental, and lifestyle aspects, proposing a dynamic evolutionary molecular theory of NPC occurrence and development; exploring NPC prevention measures through lifestyle changes, vaccination interventions, and other methods; exploring new de-escalation clinical treatment plans for NPC, constructing new strategies for precise prevention and treatment of NPC such as minimally invasive surgical treatment and de-escalation of chemoradiotherapy, etc.
Residents with a definite native place, aged 30 and 69 years at screening, and capable of long-term cooperation with screening and follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Population participating in nasopharyngeal carcinoma screening, aged between 30 and 69 years old.
Diagnostic Test: EBV antibodies test · Diagnostic Test: EBV DNA test · Other: epidemiological information survey · Other: Clinical examinations for high-risk participants · Other: EBV and human genetic sequencing
Test for VCA-IgA, EBNA1-IgA, EA-IgA, Zta-IgA, Rta-IgG and P85-Ab in nasopharyngeal brushing and plasma in plasma, saliva and nasopharyngeal brushing.
quantitative polymerase chain reaction, methylation sequencing and target sequencing of EBV DNA in nasopharyngeal brushing, saliva and plasma.
epidemiological information survey including basic conditions, dietary and lifestyle habits, social, geographical, environmental, and other information.
nasopharyngoscopy, head and neck MRI.
EB virus and human genetic sequencing for plasma, etc.
A data platform for an NPC screening cohort
A data platform, including an NPC epidemiological information database based on the gender, age, ethnicity, dietary and lifestyle habits, and geographical environmental factors, a biobank based on various samples and screening test results, and a clinical examination database based on nasopharyngoscopy, head and neck MRI, and a database for EB virus and human genetic sequencing information.
Time frame: At screening, 3 years and 10 years thereafter
Prevalence and incidence rate of nasopharyngeal carcinoma
Endoscopy combined with or without biopsy is performed to evaluate the prevalence and rate of new cases of nasopharyngeal carcinoma, in a cohort study, and to identify the associated factors related with nasopharyngeal carcinoma.
Time frame: At screening, 3 years and 10 years thereafter
Nasopharyngeal Carcinoma Death Rates
Nasopharyngeal Carcinoma deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.
Time frame: At screening, 3 years and 10 years thereafter
Death Rates From All Causes
Deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.
Time frame: At screening, 3 years and 10 years thereafter
Started Nov 2024 (actual). Primary completion is estimated for Dec 2035, 133 months after the start.
Of 52 observational studies under Nasopharyngeal Carcinoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 155. This study's planned 133 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ming-Yuan Chen